Journal
JOURNAL OF NEUROLOGY
Volume 249, Issue 6, Pages 719-722Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-002-0698-0
Keywords
polyneuropathy; chronic inflammatory demyelinating polyneuropathy; diabetes; intravenous immunoglobulin
Categories
Ask authors/readers for more resources
The authors investigated the impact of IVIg as first line treatment of diabetic patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP) concomitant with distal symmetric axonal polyneuropathy. Nine patients with these clinical and electrophysiological features were treated with IVIg (0.4 g/Kg/day for 5 days). Clinical and electrophysiological evaluations were performed before and after treatment. Following IVIg treatment there was no significant improvement in clinical deficit. However, there was a significant and persistent decrease in the Rankin scale score and an improvement in the demyelinating feature on nerve conduction studies. Our findings suggest that IVIg had small but detectable beneficial effects on diabetic patients with CIDP and a high degree of axonal damage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available